Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Zosano Pharma (ZSAN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,786
  • Shares Outstanding, K 11,973
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,360 K
  • 60-Month Beta 2.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -3.40
  • Growth Rate Est. (year over year) +29,482.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.21 +8.72%
on 04/16/19
5.54 -37.00%
on 03/21/19
-1.27 (-26.68%)
since 03/15/19
3-Month
2.05 +70.24%
on 01/18/19
6.65 -47.52%
on 02/21/19
+1.23 (+54.42%)
since 01/17/19
52-Week
1.85 +88.65%
on 12/28/18
6.65 -47.52%
on 02/21/19
-0.82 (-19.03%)
since 04/17/18

Most Recent Stories

More News
Zosano Announces the Publication of an Analysis of Acute Treatments for Migraine in Headache: The Journal of Head and Face Pain

Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company"), a clinical-stage biopharmaceutical company, today announced the peer-reviewed publication of a review and analysis of recently-completed...

ZSAN : 3.49 (+6.73%)
New Research Coverage Highlights Franklin Resources, Corporate Office Properties Trust, Guidewire Software, Bemis, T2 Biosystems, and Zosano Pharma -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Franklin Resources, Inc. (NYSE:BEN),...

GWRE : 102.05 (-1.16%)
TTOO : 2.64 (-8.01%)
BMS : 55.78 (-0.84%)
BEN : 35.55 (unch)
ZSAN : 3.49 (+6.73%)
OFC : 27.05 (-0.73%)
Zosano Announces Pricing of Public Offering of Common Stock

Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of its common stock for gross proceeds of $17.5 million,...

ZSAN : 3.49 (+6.73%)
Zosano Pharma Announces Proposed Public Offering of Common Stock

Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares...

ZSAN : 3.49 (+6.73%)
Transdermal/Transmucosal Drug Delivery System Market Size, Growth Opportunities, Trends by Manufacturers, Regions, Application & Forecast to 2024

Market Study Report newly added the Global Transdermal/Transmucosal Drug Delivery System Market Report that gives meticulous investigation of current scenario of the market size, share, demand, growth,...

DRRX : 0.58 (-3.43%)
ATRS : 2.71 (-2.52%)
CORI : 12.68 (+0.24%)
ZSAN : 3.49 (+6.73%)
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2018 Financial Results

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2018, as well as...

ZSAN : 3.49 (+6.73%)
Zosano Pharma Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 14, 2019 / Zosano Pharma Corp. (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 14, 2019, 2018 at 4:30 PM...

ZSAN : 3.49 (+6.73%)
Zosano Pharma Announces Presentation and Participation at the 31st Annual Roth Conference

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker, will participate in a panel titled...

ZSAN : 3.49 (+6.73%)
Zosano Pharma to Host Conference Call on Fourth Quarter and Full Year 2018 Financial Results and Provide Operational and Strategic Update

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Thursday, March 14, 2019 at 4:30 p.m. ET to discuss...

ZSAN : 3.49 (+6.73%)
Detailed Research: Economic Perspectives on Zosano Pharma, Appian, Ross Stores, Alleghany, ZAGG, and Lindsay -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Zosano Pharma Corporation (NASDAQ:ZSAN),...

APPN : 32.59 (+0.71%)
ROST : 99.92 (+1.05%)
Y : 637.54 (-0.35%)
ZSAN : 3.49 (+6.73%)
LNN : 87.02 (+0.27%)
ZAGG : 8.82 (+0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade ZSAN with:

Business Summary

Zosano Pharma Corporation is a biopharmaceutical company. It is engaged in developing a transdermal micro needle patch system to deliver formulations of existing drugs through the skin for the treatment of a variety of indications. The Company's lead product candidates include Weekly ZP-PTH for severe...

See More

Key Turning Points

2nd Resistance Point 3.81
1st Resistance Point 3.65
Last Price 3.49
1st Support Level 3.32
2nd Support Level 3.15

See More

52-Week High 6.65
Fibonacci 61.8% 4.82
Fibonacci 50% 4.25
Fibonacci 38.2% 3.68
Last Price 3.49
52-Week Low 1.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar